Table 3.

Multivariable regression models of LVMI and LVH

Model	LVMI (in the Log Scale) Girls versus Boys, % (95% CI)	Odds of LVH among Girls versus Boys (95% CI)
Base model	−3.6 (−7.3 to +0.2)	2.30 (1.44 to 3.67)
Base model+Tanner stage	−4.9 (−8.5 to −1.1)	2.25 (1.40 to 3.63)
Base model+high triglycerides	−3.5 (−9.2 to +0.5)	2.17 (1.33 to 3.52)
Base model+FGF23	−1.9 (−6.7 to +3.1)	3.08 (1.74 to 5.44)
Base model+Vitamin D-1,25 DOH	−4.1 (−8.2 to +0.3)	1.97 (1.12 to 3.48)
Base model+Vitamin D-25 OH	−4.1 (−8.3 to +0.3)	1.99 (1.12 to 3.51)
Based model+Tanner stage+high triglycerides+FGF23+Vitamin D-1,25 DOH+Vitamin D-25 OH	−3.6 (−9.1 to +2.2)	2.11 (1.04 to 4.31)

Base models all adjusted for visit, systolic BP z-score (by visit), height (by visit), eGFR, race (black versus other), anemia, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, other antihypertensive medications, age, CKD duration, percent life with CKD, and glomerular diagnosis. LVMI, left ventricular mass index; LVH, left ventricular hypertrophy; 95% CI, 95% confidence interval; FGF23, fibroblast growth factor 23; Vitamin D-1,25 DOH, 1,25-dihydroxyvitamin D; Vitamin D-25 OH, 25-hydroxyvitamin D.